These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28861778)

  • 21. Mammalian prion amyloid formation in bacteria.
    Macedo B; Cordeiro Y; Ventura S
    Prion; 2016 Mar; 10(2):112-8. PubMed ID: 26910379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble polymorphic bank vole prion proteins induced by co-expression of quiescin sulfhydryl oxidase in E. coli and their aggregation behaviors.
    Abskharon R; Dang J; Elfarash A; Wang Z; Shen P; Zou LS; Hassan S; Wang F; Fujioka H; Steyaert J; Mulaj M; Surewicz WK; Castilla J; Wohlkonig A; Zou WQ
    Microb Cell Fact; 2017 Oct; 16(1):170. PubMed ID: 28978309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental Models of Inherited PrP Prion Diseases.
    Watts JC; Prusiner SB
    Cold Spring Harb Perspect Med; 2017 Nov; 7(11):. PubMed ID: 28096244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian prion protein (PrP) forms conformationally different amyloid intracellular aggregates in bacteria.
    Macedo B; Sant'Anna R; Navarro S; Cordeiro Y; Ventura S
    Microb Cell Fact; 2015 Nov; 14():174. PubMed ID: 26536866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.
    Ferreira NC; Ascari LM; Hughson AG; Cavalheiro GR; Góes CF; Fernandes PN; Hollister JR; da Conceição RA; Silva DS; Souza AMT; Barbosa MLC; Lara FA; Martins RAP; Caughey B; Cordeiro Y
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of recombinant serpins in Escherichia coli.
    Pearce MC; Cabrita LD
    Methods Enzymol; 2011; 501():13-28. PubMed ID: 22078528
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary Human Prion Diseases: an Update.
    Schmitz M; Dittmar K; Llorens F; Gelpi E; Ferrer I; Schulz-Schaeffer WJ; Zerr I
    Mol Neurobiol; 2017 Aug; 54(6):4138-4149. PubMed ID: 27324792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of divalent cations on elk prion protein fibril formation and stability.
    Samorodnitsky D; Nicholson EM
    Prion; 2018 Jan; 12(1):63-71. PubMed ID: 29310497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pressure Reveals Unique Conformational Features in Prion Protein Fibril Diversity.
    Torrent J; Martin D; Noinville S; Yin Y; Doumic M; Moudjou M; Béringue V; Rezaei H
    Sci Rep; 2019 Feb; 9(1):2802. PubMed ID: 30808892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid-liquid phase separation and fibrillation of the prion protein modulated by a high-affinity DNA aptamer.
    Matos CO; Passos YM; do Amaral MJ; Macedo B; Tempone MH; Bezerra OCL; Moraes MO; Almeida MS; Weber G; Missailidis S; Silva JL; Uversky VN; Pinheiro AS; Cordeiro Y
    FASEB J; 2020 Jan; 34(1):365-385. PubMed ID: 31914616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular approaches to mechanisms of prion diseases.
    Bratosiewicz-Wasik J; Wasik TJ; Liberski PP
    Folia Neuropathol; 2004; 42 Suppl A():33-46. PubMed ID: 15449458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of N-glycosylation site variants during human PrP aggregation and fibril nucleation.
    Mishra R; Elgland M; Begum A; Fyrner T; Konradsson P; Nyström S; Hammarström P
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):909-921. PubMed ID: 30935958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the purification of biologically active IL-7 cytokine expressed in Escherichia coli and Pichia pastoris.
    Zaremba-Czogalla M; Stumpp C; Bonifacio E; Paul R
    Protein Expr Purif; 2015 Jun; 110():65-71. PubMed ID: 25703052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and Fibrillation of Recombinant Human Amyloid-β, Prion Protein, and Tau Under Native Conditions.
    Sandberg A; Nyström S
    Methods Mol Biol; 2018; 1779():147-166. PubMed ID: 29886532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing Mutations Significantly Inhibit Amyloid Formation by Human Prion Protein and Decrease Its Cytotoxicity.
    Huang JJ; Li XN; Liu WL; Yuan HY; Gao Y; Wang K; Tang B; Pang DW; Chen J; Liang Y
    J Mol Biol; 2020 Feb; 432(4):828-844. PubMed ID: 31821812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of methionine oxidation in E200K prion protein misfolding: Implications for the mechanism of pathogenesis in E200K linked familial Creutzfeldt-Jakob disease.
    Wang Z; Feng B; Xiao G; Zhou Z
    Biochim Biophys Acta; 2016 Apr; 1864(4):346-58. PubMed ID: 26779934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Structure of Mammalian Prions and Their Aggregates.
    Vázquez-Fernández E; Young HS; Requena JR; Wille H
    Int Rev Cell Mol Biol; 2017; 329():277-301. PubMed ID: 28109330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell Biology Approaches to Studying Prion Diseases.
    Priola SA
    Methods Mol Biol; 2017; 1658():83-94. PubMed ID: 28861784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.